- Previous Close
4.3900 - Open
4.2403 - Bid --
- Ask --
- Day's Range
4.2400 - 4.2403 - 52 Week Range
3.5660 - 12.6000 - Volume
736 - Avg. Volume
2,347 - Market Cap (intraday)
20.34M - Beta (5Y Monthly) 1.32
- PE Ratio (TTM)
-- - EPS (TTM)
-9.8900 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.33
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
www.polypid.comRecent News: PYPD
Performance Overview: PYPD
Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PYPD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PYPD
Valuation Measures
Market Cap
20.34M
Enterprise Value
17.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.85
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.19%
Return on Equity (ttm)
-261.37%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.25M
Diluted EPS (ttm)
-9.8900
Balance Sheet and Cash Flow
Total Cash (mrq)
14.46M
Total Debt/Equity (mrq)
159.58%
Levered Free Cash Flow (ttm)
--